Zhivolupov S A, Rashidov N A, Samartsev I N, Jakovlev E V
Kirov Military Medical Academy, St. Petersburg.
Medical Center 'Admiralteyskie Verfi', St. Petersburg.
Zh Nevrol Psikhiatr Im S S Korsakova. 2015;115(10 Pt 2):22-27. doi: 10.17116/jnevro201511510222-27.
To evaluate the cognitive changes in patients with mild to moderate Alzheimer's disease after the treatment with acetylcholinesterase inhibitors - neuromidin and galantamine.
Fifty-eight patients with probable Alzheimer's disease, aged 60-84 years (mean 73.2±6.7), were enrolled in a 20-week double-blind parallel group study. All patients were randomized in 2 groups: group 1 (n=28) received neuromidin, group 2 (n=30) - galantamine. Treatment efficacy was evaluated with the ADAS-cog/11 scale.
Both drugs significantly improved or stabilized cognitive function in the patients. The most marked changes were obtained in the group of patients treated with neuromidin (р<0.05).
The results suggest that the effectiveness of anticholinesterase treatment of Alzheimer's disease could be determined not only by the central but also peripheral cholinergic action.
评估轻度至中度阿尔茨海默病患者在接受乙酰胆碱酯酶抑制剂——奈非西坦和加兰他敏治疗后的认知变化。
58例年龄在60 - 84岁（平均73.2±6.7岁）的可能患有阿尔茨海默病的患者参加了一项为期20周的双盲平行组研究。所有患者随机分为2组：第1组（n = 28）接受奈非西坦，第2组（n = 30）接受加兰他敏。使用ADAS-cog/11量表评估治疗效果。
两种药物均显著改善或稳定了患者的认知功能。在接受奈非西坦治疗的患者组中获得了最显著的变化（р<0.05）。
结果表明，阿尔茨海默病抗胆碱酯酶治疗的有效性不仅可以由中枢胆碱能作用决定，还可以由外周胆碱能作用决定。
